NetworkNewsBreaks – QSAM Biosciences Inc. (QSAM)
Post# of 51
(Total Views: 191)
Posted On: 10/26/2022 5:04:26 PM
NetworkNewsBreaks – QSAM Biosciences Inc. (QSAM) Announces Approval of Second Clinical Trial Site for Phase 1 Study
QSAM Biosciences (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP, or CycloSam(R), for the treatment of bone cancer and related diseases, has added Rutgers Cancer Institute of New Jersey (“RCINJ”) as a clinical trial site for its phase 1 CycloSam study. RCINJ has been approved to begin enrolling patients into the study, which will evaluate the effectiveness of CycloSam in treating patients with bone cancer. According to the announcement, RCINJ is part of Rutgers Health and is New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center, a designation granted to institutions based on scientific leadership, resources and track record of research discoveries. RCINJ is the second trial site approved to enroll patients in the multiple-center, dose-escalation clinical trial. Eligible patients are those with bone cancer that has metastasized from the breast, prostate, lung or other organs, as well osteosarcoma and Ewing’s Sarcoma bone cancer patients. “The addition of Rutgers as our second clinical trial site will allow us to advance our study more rapidly in this major northeast population center,” said QSAM Biosciences CEO Douglas R. Baum in the press release. “We are pleased and honored to have the participation of the outstanding Rutgers CINJ team, who brings a substantial depth of knowledge and clinical development experience to our trials for CycloSam.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
QSAM Biosciences (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP, or CycloSam(R), for the treatment of bone cancer and related diseases, has added Rutgers Cancer Institute of New Jersey (“RCINJ”) as a clinical trial site for its phase 1 CycloSam study. RCINJ has been approved to begin enrolling patients into the study, which will evaluate the effectiveness of CycloSam in treating patients with bone cancer. According to the announcement, RCINJ is part of Rutgers Health and is New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center, a designation granted to institutions based on scientific leadership, resources and track record of research discoveries. RCINJ is the second trial site approved to enroll patients in the multiple-center, dose-escalation clinical trial. Eligible patients are those with bone cancer that has metastasized from the breast, prostate, lung or other organs, as well osteosarcoma and Ewing’s Sarcoma bone cancer patients. “The addition of Rutgers as our second clinical trial site will allow us to advance our study more rapidly in this major northeast population center,” said QSAM Biosciences CEO Douglas R. Baum in the press release. “We are pleased and honored to have the participation of the outstanding Rutgers CINJ team, who brings a substantial depth of knowledge and clinical development experience to our trials for CycloSam.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)QSAM Biosciences Inc. (QSAM) Stock Research Links
Scroll down for more posts ▼